Business Context and Reporting Period
This Form 8-K is a current report filed by Abbott Laboratories on November 25, 2009, regarding a specific corporate event. The report was signed on November 30, 2009, by Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal agreement and does not contain financial performance data.
Material Changes and Events
Under Item 8.01 (Other Events), Abbott Laboratories and Laboratories Fournier S.A. (the patent owner) entered into a license agreement with Teva Pharmaceuticals USA Inc. Key terms include:
- Teva is granted rights to intellectual property for Tricor 145 mg.
- These rights become effective no sooner than March 28, 2011.
- Under certain defined circumstances, the rights may be delayed until July 1, 2012.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements under the Private Securities Litigation Reform Act of 1995. Abbott notes that actual results may differ materially due to economic, competitive, governmental, and technological factors. Specific risk factors are referenced in Item 1A of the company's 2008 Form 10-K. Abbott explicitly states it undertakes no obligation to publicly revise forward-looking statements based on subsequent events.
Investor Verification Checklist
- Verify the specific "defined circumstances" that could delay Teva's rights to Tricor intellectual property until July 1, 2012.
- Review the 2008 Form 10-K Item 1A for detailed risk factors affecting Abbott's operations.
- Confirm the impact of this generic licensing agreement on Abbott's future revenue projections for Tricor.